$809 Million is the total value of Boxer Capital, LLC's 24 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BGNE | Buy | BEIGENE LTDsponsored adr | $126,234,000 | +16.3% | 900,000 | +42.9% | 15.60% | +29.5% |
| SLDB | Buy | SOLID BIOSCIENCES INC | $93,754,000 | -31.0% | 3,498,272 | +21.4% | 11.58% | -23.2% |
| PTCT | PTC THERAPEUTICS INC | $73,960,000 | -27.0% | 2,155,000 | 0.0% | 9.14% | -18.7% | |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $69,366,000 | -12.8% | 1,650,000 | +3.7% | 8.57% | -2.9% |
| MRTX | MIRATI THERAPEUTICS INC | $66,411,000 | -9.9% | 1,565,560 | 0.0% | 8.20% | +0.3% | |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $60,474,000 | – | 600,000 | +100.0% | 7.47% | – |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $55,200,000 | -9.5% | 1,200,000 | -12.7% | 6.82% | +0.7% |
| ODT | Buy | ODONATE THERAPEUTICS INC | $41,941,000 | -23.6% | 2,978,762 | +5.4% | 5.18% | -14.9% |
| QURE | New | UNIQURE NV | $34,584,000 | – | 1,200,000 | +100.0% | 4.27% | – |
| RCKT | ROCKET PHARMACEUTICALS INC | $29,137,000 | -39.8% | 1,966,051 | 0.0% | 3.60% | -33.0% | |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $28,890,000 | -14.2% | 4,500,000 | +200.0% | 3.57% | -4.5% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $28,735,000 | – | 700,000 | +100.0% | 3.55% | – |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $20,415,000 | -3.5% | 1,500,000 | +15.4% | 2.52% | +7.5% |
| CBAY | CYMABAY THERAPEUTICS INC | $16,480,000 | -29.0% | 2,094,000 | 0.0% | 2.04% | -20.9% | |
| IMMU | New | IMMUNOMEDICS INC | $16,411,000 | – | 1,150,000 | +100.0% | 2.03% | – |
| KURA | KURA ONCOLOGY INC | $11,861,000 | -19.8% | 844,789 | 0.0% | 1.46% | -10.7% | |
| KNSA | Sell | KINIKSA PHARMACEUTICALS LTD | $8,162,000 | -72.7% | 290,577 | -75.2% | 1.01% | -69.6% |
| MEIP | MEI PHARMA INC | $7,691,000 | -38.7% | 2,913,091 | 0.0% | 0.95% | -31.8% | |
| New | ESPERION THERAPEUTICS INC NEcall | $4,600,000 | – | 100,000 | +100.0% | 0.57% | – | |
| MDCO | Sell | MEDICINES CO | $4,440,000 | -89.4% | 232,000 | -83.4% | 0.55% | -88.2% |
| KALV | KALVISTA PHARMACEUTICALS INC | $3,950,000 | -10.7% | 200,000 | 0.0% | 0.49% | -0.6% | |
| MTNB | New | MATINAS BIOPHARMA HLDGS INC | $3,358,000 | – | 5,642,858 | +100.0% | 0.42% | – |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $2,805,000 | -91.4% | 50,000 | -87.5% | 0.35% | -90.4% |
| NVUS | NOVUS THERAPEUTICS INC | $519,000 | -65.7% | 324,383 | 0.0% | 0.06% | -61.9% | |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.09% | – |
| BLPH | Exit | BELLEROPHON THERAPEUTICS INC | $0 | – | -1,482,143 | -100.0% | -0.18% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.44% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -1,697,802 | -100.0% | -0.45% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -2,125,000 | -100.0% | -0.47% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -2,321,900 | -100.0% | -0.83% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BEIGENE LTD | 34 | Q2 2024 | 15.6% |
| MIRATI THERAPEUTICS INC | 33 | Q4 2023 | 55.2% |
| ROCKET PHARMACEUTICALS INC | 26 | Q2 2024 | 5.4% |
| KURA ONCOLOGY INC. | 26 | Q2 2024 | 4.7% |
| DBV TECHNOLOGIES S A | 26 | Q2 2024 | 3.9% |
| IDEAYA BIOSCIENCES INC | 21 | Q2 2024 | 4.8% |
| AKERO THERAPEUTICS INC | 21 | Q2 2024 | 4.5% |
| MILESTONE PHARMACEUTICALS INC | 21 | Q2 2024 | 2.6% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SPRINGWORKS THERAPEUTICS INC | 20 | Q2 2024 | 8.3% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| iTeos Therapeutics, Inc. | May 14, 2024 | 2,946,915 | 8.1% |
| Century Therapeutics, Inc. | April 22, 2024 | 4,901,603 | 5.8% |
| PMV Pharmaceuticals, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| FATE THERAPEUTICS INC | February 12, 2024 | 6,171,000 | 6.3% |
| Tyra Biosciences, Inc. | February 08, 2024 | 6,448,359 | 12.3% |
| Mirati Therapeutics, Inc. | January 25, 2024 | ? | ? |
| Nkarta, Inc. | January 18, 2024 | 4,407,350 | 9.0% |
| Rain Oncology Inc. | December 18, 2023 | 2,933,152 | 9.9% |
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-28 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-07-18 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-14 |
| SC 13D/A | 2024-05-14 |
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.